GET THE APP

Interesting Collision between an Indolent B-Cell Lymphoma and a Microsatellite Unstable Adenocarcinoma of the Colon
Journal of Hematology & Thromboembolic Diseases

Journal of Hematology & Thromboembolic Diseases
Open Access

ISSN: 2329-8790

+44 20 3868 9735

Case Report - (2013) Volume 1, Issue 2

Interesting Collision between an Indolent B-Cell Lymphoma and a Microsatellite Unstable Adenocarcinoma of the Colon

Rebecca A Redman and Jason Chesney*
Department of Medicine, Division of Medical Oncology and Hematology, University of Louisville School of Medicine, USA
*Corresponding Author: Jason Chesney, M.D, Ph.D, Clinical and Translational Research Building #424, 505 South Hancock Street, Louisville, Kentucky, USA Email:

Abstract

Neoplastic transformation of lymphocytes involves a multitude of genetic alterations that result in clonal expansion. Cognate activation of lymphocytes against foreign and self antigens similarly results in clonal expansion and there have been prior reports of simultaneous clinical presentations of lymphomas and autoimmune disorders. In this case report, we report a rare collision of an indolent B cell lymphoma with a MLH1- negative microsatellite unstable colon cancer. We present a hypothesis whereby repeated immune stimulation by tumor neopeptide antigens predisposes otherwise normal B cells to neoplastic transformation. We believe that this case provides hypothesis-generating clinical data for improving our understanding of the interplay between B cell activation and their potential to transform into lymphoma cells.

Introduction

The synchronous presentation of two primary malignancies is rare, even more so when two malignancies coexist within the same location as in the case of a collision tumor. While collision tumors involving colonic adenocarcinomas have been reported [1-4], those involving an indolent B-cell lymphoma are somewhat rare. In addition, whereas defects in DNA repair pathways, in particular mismatch repair, are well described in colorectal adenocarcinoma, no prior reports that address this issue in collision tumors are present in the PubMed database. Defects in DNA mismatch repair occur in 10-15% of sporadic colorectal cancers and are the hallmark of Hereditary Nonpolyposis Colorectal Cancer (HNPCC)- associated malignancies [5]. Loss of a mismatch repair protein occurs via germline mutation in those with HNPCC or Lynch syndrome, and most commonly by promoter hypermethylation of the DNA mismatch repair gene MutL homolog 1 (MLH1) in sporadic cases, both of which result in microsatellite instability. Interestingly, these tumors exhibit a markedly intense lymphoid reaction, which can include peritumoral Crohn’s-like and/or intratumoral lymphocytic infiltration [6]. We report herein an interesting case of a MLH1-deficient adenocarcinoma of the colon in which an associated lymphoid infiltrate was diagnosed as an indolent B-cell lymphoma.

Case Report

A 54 year-old male with epilepsy presented to the emergency department with several days of progressive abdominal pain and distension. CT imaging of the abdomen and pelvis revealed a colonic mass at the hepatic flexure with fat stranding and diffuse lymphadenopathy as well as marked splenomegaly (Figure 1). Physical exam was significant for a palpable spleen that extended below the level of the umbilicus. There was no palpable peripheral lymphadenopathy. Laboratory evaluation revealed pancytopenia with a white blood cell count of 3400/mm3, hemoglobin of 10.3 gm/dL, and a platelet count of 80,000/mm3. Colonoscopy demonstrated an ulcerated circumferential non-bleeding mass in the hepatic flexure, but no other obvious mucosal irregularities. Histopathological analyses of biopsied tissue confirmed colon adenocarcinoma. Bone marrow biopsy and aspiration demonstrated maturing trilineage hematopoiesis. However, within the aspirate cell clot, aggregates of small lymphocytes, occupying approximately 5% of the marrow cellularity, were identified. By flow cytometry, a monoclonal B-cell population comprising 1.1% of total cellular events was detected with the following immunophenotype: CD19+, CD20+, CD22+, CD79b+, CD5-, CD10-, CD43-, CD25-, and CD103-. Serum protein electrophoresis did not reveal the presence of a paraprotein. Taken together, these data indicated that the patient’s bone marrow contained a B cell lymphoproliferative disorder most consistent with splenic marginal zone lymphoma or MALT lymphoma.

Thromboembolic-Diseases-CT-Imaging-Reveals-Right-Hepatic-Flexure-Mass

Figure 1: CT Imaging Reveals Right Hepatic Flexure Mass, Mesenteric Lymphadenopathy and Splenomegaly. CT images were captured pre-surgery that revealed a hepatic flexure colon tumor (top) and lymphadenopathy and splenomegaly (Bottom). Post-surgery and after one month of rituximab, the lymphadenopathy/splenomegaly improved. Arrows indicate the tissue of interest.

Shortly thereafter, the patient underwent an uncomplicated open right hemicolectomy revealing a moderately differentiated adenocarcinoma arising from a tubulovillous adenoma. The tumor measured 6 cm, penetrating through the muscularis propria into the pericolonic fat. Immunohistochemical stains were consistent with loss of the mismatch repair proteins MLH1 and PMS2 but not of MSH2 and MSH6, which is consistent with a diagnosis of either Lynch syndrome or sporadic colorectal carcinoma with high microsatellite instability (Figure 2). Forty lymph nodes were negative for metastatic adenocarcinoma, although multiple enlarged lymph nodes were scattered throughout the pericolonic adipose tissue. In addition, several lymphoid aggregates intimately associated with the adenocarcinoma were noted. Morphologically, the lymphocytes present in the lymphoid aggregates and in the lymph nodes appeared similar to those identified in the bone marrow aspirate cell clot. Immunohistochemistry revealed these cells to express CD20 and Bcl-2 (Figure 3) but not CD3 (data not shown). B-cell gene rearrangement studies of the variable and joining regions of the immunoglobulin heavy chain gene confirmed that these cells represented a monoclonal population of B cells (data not shown). Viral hepatitis serologies were negative. Based on a presumed diagnosis of splenic marginal zone lymphoma, the patient received four weekly doses of rituximab, which resulted in only minimal improvement in the degree of splenomegaly and stable lymphadenopathy (Figure 1). On follow up five months later, the spleen had increased in size and bendamustine was added to his treatment regimen, resulting in marked improvement in splenomegaly (Figure 1).

Thromboembolic-Diseases-Colon-Tumor-MLH1-PMS2-MSH2-MSH6-Indicating-Sporadic

Figure 2: Colon Tumor Is MLH1-/PMS2-/MSH2+/MSH6+ Indicating a Sporadic Colorectal Carcinoma with High Mirosatellite Instability. Resected tumor was fixed in formalin, embedded in paraffin and stained for MLH1, PMS2, MSH2 and MSH6 expression by immunohistochemistry with antibodies obtained from Millipore (dilutions = 1:100, 1:200, 1:1000 and 1:500, respectively). No MLH1 or PMS2 expression was detected which is consistent with a sporadic colorectal carcinoma.

Thromboembolic-Diseases-Histology-Infiltrating-Atypical-Lymphocytes-Adjacent-Lymph

Figure 3: Histology of Infiltrating Atypical Lymphocytes and Adjacent Lymph Nodes Indicate a CD20+ B Cell Lymphoproliferative Disorder. Resected tumor (left) and adjacent lymph nodes (right) were examined by H&E staining and CD20/Bcl-2 immunohistochemistry (Millipore; 1:200 and 1:100, respectively). CD20+ cells were found to infiltrate the colon adenocarcinoma and to replace most of the normal architecture of the lymph nodes.

Discussion

Although the flow cytometric (CD20+/CD79b+) and immunohistochemical (CD20+) analyses as well as clinical presentation (splenomegaly) suggested that the patient may have had splenic marginal zone lymphoma [7,8], the infiltration into colon was somewhat atypical for this type of lymphoma. Indeed, collision tumors can sometimes confound an otherwise straightforward diagnosis. In addition, the simultaneous diagnosis of a B cell lymphoma and a colon adenocarcinoma would typically pose a therapeutic dilemma. However, this was less of an issue in this patient as fluorouracilbased chemotherapy regimens do not benefit patients with stage II microsatellite unstable colon cancers [9]. Accordingly, the patient’s only treatment for his colon cancer consisted of surgical resection and the choice of chemotherapy was based solely on his lymphoma.

Aside from treatment considerations, there is the question of if and how these two cancers might affect one another’s natural history? The relative rarity of collision tumors would seem to suggest that the coexistence of two malignancies in the same location is only by chance. Although the influence of one cancer on the other is largely unknown, certain pro-neoplastic cytokines that are released by tumor cells have paracrine activities. For example, the immunosuppressive cytokine transforming growth factor (TGF) - promotes tumor growth through the inhibition of the proliferation and activity of tumor antigenspecific CD8+ T cells which normally function to lyse tumor cells [10]. Certainly, one could envision a situation whereby one tumor type is secreting TGF-, not only cloaking the source tumors but also any adjacent disparate tumors (Figure 4). Another possible mechanism by which one tumor type might benefit from its collision counterpart is via the stimulation of angiogenesis. Oncogenic Ras signaling enhances the expression of the pro-angiogenic cytokine vascular endothelial growth factor (VEGF) [11,12] and one tumor type might gain the ability to secrete VEGF via genetic alterations that activate Ras signaling which could promote neo-vascularization to support an adjacent disparate tumor (Figure 4).

Thromboembolic-Diseases-Potential-Mechanisms-for-Collision-B-Cell-Lymphoma

Figure 4: Potential Mechanisms for the Collision of a B Cell Lymphoma With an Adenocarcinoma. Tumor-infiltrating B cells are activated and proliferating which predisposes the cells to neoplastic transformation. Ras-transformed tumors copiously secrete VEGF which promotes angiogenesis. Tumor cells frequently secrete TGFwhich suppresses CD8+ T cell activation and thus suppresses tumor immunity.

Microsatellite unstable colon tumors display a major lymphocyte infiltration and it has been hypothesized that this is due to immune priming by neopeptide antigens created through frameshift and insertion/deletion mutations [13,14]. Matched stage for stage, patients with colon cancer displaying microsatellite instability have a better prognosis than their counterparts with microsatellite stable tumors and are less likely to have metastatic disease at the time of presentation [15]. This improvement in clinical prognosis may result from the expansion of these neopeptide-specific T and B cells and resultant immunebased control of the colon adenocarcinoma proliferative capacity and invasiveness. Neoplastic transformation of normal B cells into B cell lymphoma cells is a multi-step process that requires the loss of cell cycle checkpoints and resistance to apoptosis. We speculate that, in the case of our patient, infiltrating and activated normal B cells were predisposed to transformation via increased activation of proproliferative and mutagenic regulatory proteins such as cyclin dependent kinases. In other words, this pre-disposition may have “set the stage” for a normal B cell clone to more readily transform into an atypical B cell lymphoma. In support of this hypothesis, splenic marginal zone lymphomas have been reported to occur during the course of autoimmunities that are characterized by normal B cell activation and proliferation [8]. Although an alternative explanation could involve the simultaneous loss of MLH1 and resultant microsatellite instability in the infiltrating B cells, microsatellite instability is exceedingly rare in B cell lymphomas [15].

In conclusion, we have reported the rare collision of an indolent B cell lymphoma and a MLH1-negative microsatellite unstable colon cancer. We believe this clinical case may provide insight into the interplay between B cell activation and their potential for neoplastic transformation.

References

  1. Mannweiler S, Dinges HP, Beham-Schmid C, Hauser H, Starlinger M, et al. (2003) Colliding / concomitant tumors of the intestine: report of 3 cases. Pathol Oncol Res 9: 188-192.
  2. Sasaki S, Hatanaka K, Sahara N, Uekusa T, Hirayama K, et al. (2010) Collision tumor of primary malignant lymphoma and adenocarcinoma in the colon: report of a case. Surg Today 40: 975-981.
  3. Silvestris N, Zito FA, Fiore MG, Simone G, Tommasi S, et al. (2011) Synchronous presentation of B-cell chronic lymphocytic leukemia/small-cell lymphoma and colon adenocarcinoma within the same mesenteric lymph nodes and a single liver metastasis. J Clin Oncol 29: e11-13.
  4. Argyropoulos T, Foukas P, Kefala M, Xylardistos P, Papageorgiou S, et al. (2012) Simultaneous occurrence of colonic adenocarcinoma and MALT lymphoma: A series of three cases. World J Gastrointest Oncol 4: 89-93.
  5. Kim H, Jen J, Vogelstein B, Hamilton SR (1994) Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 145: 148-156.
  6. Alexander J, Watanabe T, Wu TT, Rashid A, Li S, et al. (2001) Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 158: 527-535.
  7. Bennett M, Schechter GP (2010) Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab. Semin Hematol 47: 143-147.
  8. Zinzani PL (2012) The many faces of marginal zone lymphoma. Hematology Am Soc Hematol Educ Program 2012: 426-432.
  9. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, et al. (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349: 247-257.
  10. Smith AL, Robin TP, Ford HL (2012) Molecular pathways: targeting the TGF-ß pathway for cancer therapy. Clin Cancer Res 18: 4514-4521.
  11. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, et al. (1995) Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55: 4575-4580.
  12. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D (2011) RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 11: 761-774.
  13. Saeterdal I, Bjørheim J, Lislerud K, Gjertsen MK, Bukholm IK, et al. (2001) Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A 98: 13255-13260.
  14. Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, et al. (2008) Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 134: 988-997.
  15. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, et al. (2000) Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342: 69-77.
Citation: Redman RA, Chesney J (2013) Interesting Collision between an Indolent B-Cell Lymphoma and a Microsatellite Unstable Adenocarcinoma of the Colon. J Hematol Thromb Dis 1:110.

Copyright: © 2013 Redman RA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.